Patients with ovarian clear cell carcinoma (OCCC) whose tumors have specific mutations in the PPP2R1A gene were found to have improved survival following immunotherapy compared to patients without ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses results from a phase 2 trial of pembrolizumab and ...

BI-1808 and pembrolizumab combination shows a 24% ORR in recurrent ovarian cancer, surpassing pembrolizumab monotherapy's 8% ...

The LARA trial (NCT04699071), a multi-center, single-arm, phase 2 study, found that combining pembrolizumab (Keytruda) with ...

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced an expansion of its collaboration with The University of Texas ...

When Caitlin Delaney was diagnosed with a rare and aggressive form of ovarian cancer as a mother with two young children, she ...